Expression of transforming growth factor beta receptor I and II in chronic rhinosinusitis, nasal polyps and normal nasal mucosa tissues
To explore the expression of transforming growth factor beta receptor(TGFpR) I, II in the chronic rhinosinusitis, nasal polyps and normal nasal mucosa tissues.
The protein expression of the TGFbetaR I and TGFbetaR II were determined by means of immunohistochemistry in chronic rhinosinusitis tissues from 25 patients, nasal polyps tissues from 21 patients and inferior turbinate mucosa tissues from 17 patients with deviation of nasal septum.
(1) In chronic rhinosinusitis and nasal polyps tissues, compared with controls, the expression of TGFbetaR I and TGFbetaR II protein was increased significantly (P < 0.01). (2) The expression of TGFbetaR I and TGFbetaR II protein in nasal polyps tissues was significant increased than that in chronic rhinosinusitis tissues (P < 0.01).
The different expression level and pattern of TGFbetaR I and TGFbetaR II in chronic rhinosinusitis and nasal polyps tissues indicates TGFbetaR may play a different role in the pathogenesis chronic rhinosinusitis and nasal polyps.
Available from: Rogério Pezato
- "There is discrepant information on TGF-β1 expression in CRSwNP. Some authors have reported greater expression of TGF-β1 in patients with CRSwNP as compared with healthy subjects, [5-8] while other authors found the opposite [9,10]. "
[Show abstract] [Hide abstract]
ABSTRACT: To evaluate TGF-β1 expression in polypoid mucosa (epithelium and stroma) of patients with chronic rhinosinusitis with nasal polyposis (CRSwNP).
Cross-sectional study with two groups: 17 patients with nasal polyposis and 11 controls. Polyps and normal nasal mucosa were processed by immunohistochemical methods for TGF-β1 visualization. Then, the percentage of TGF-β1 expression in stroma and epithelium was objectively quantified using UT Morph software.
A lower percentage of positive expression was found in the epithelium of CRSwNP patients (32.44%) versus normal controls (55.91%) (p < 0.05), and a higher percentage of positive expression in the stroma of CRSwNP patients (23.24%) versus controls (5.88%) (p < 0.05).
The lower percentage of TGF-β1 expression in the nasal epithelium of CRSwNP patients may have an impact on epithelium-directed topical treatments employed in this patient population.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale 04/2013; 42(1):29. DOI:10.1186/1916-0216-42-29 · 0.89 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: TGF-beta is a multi-functional cytokine with a huge array of effects on a variety of cell types. It is rapidly emerging as a key major player in the way the airway epithelium behaves and its ability to repair itself. This is not only of relevance to allergic airway diseases such as asthma and allergic rhinitis, which are increasing in prevalence worldwide, but in many other diseases. The full impact any disruption of TGF-beta signalling may have in the development and persistence of allergic inflammatory airway diseases is yet to be fully realized and remains the subject of ongoing research. There has been a recent revival of interest in the role of regulatory T cells in controlling allergic inflammation. Evidence is emerging of a significant contribution by TGF-beta to this regulatory process. This review aims to summarize current knowledge relating to TGF-beta in relation to allergic inflammatory upper airways disease, and attempts to clarify some of the discrepancies and inconsistencies in this area. It also considers the therapeutic implications of novel TGF-beta therapy, including potential future applications in the treatment of nasal polyposis and reduction of post-operative scar tissue formation following endoscopic sinus surgery.
Clinical & Experimental Allergy 05/2009; 39(8):1128-35. DOI:10.1111/j.1365-2222.2009.03239.x · 4.77 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.